Promedico Ltd.
Privately held: no public share price
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | XPO1 (exportin-1)Small molecule | Multiple MyelomaMyelofibrosisEndometrial Cancer |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (2)
Regulatory and conference events
(10)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
17 November 2026Filing acceptedSelinexorFDA accepts the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗
31 August 2026Filing submittedSelinexor (Xpovio)Karyopharm submits an sNDA to FDA for XPOVIO plus ruxolitinib in myelofibrosis (accelerated approval, Priority Review requested)
US, FDA · Karyopharm Therapeutics Inc. · Source ↗
30 July 2026Topline resultSelinexor (Xpovio)Phase 3 XPORT-EC-042 (NCT05611931) of selinexor maintenance in endometrial cancer did not meet its PFS primary endpoint
Global · Karyopharm Therapeutics Inc. · Source ↗
24 March 2026Topline resultSelinexor (Xpovio)Phase 3 SENTRY (NCT04562389) met its first co-primary endpoint (SVR35) and missed its second (Abs-TSS)
Global · Karyopharm Therapeutics Inc. · Source ↗
March 2026WithdrawalSelinexorAccelerated approval in DLBCL voluntarily withdrawn at the FDA's request
US, FDA · Source ↗
Financial reports
No financial reports recorded.